1[1]Kris M, Herbst R, Rischin D, et al. Objective regressions in nonsmall cell lung cancer patients treated in phase Ⅰ trials of oral ZD1839 (Iressa), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR) [J]. Lung Cancer,2000,29 (suppl 1, abstr 231):72
2[2]Shepherd F, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinumbased chemotherapy [J]. J Clin Oncol, 2000,18:2095-2103
2PERRAIS M,PIGNY P,COPIN M C,et al.Induction of MUC2 and MUC5AC mucins by factors of the epidermal growth factor (EGF) family is mediated by EGF receptor/Ras/Raf/extracelllular signal-regulatedkinase cascade and Sp1[J].J Biol Chem,2002,277(35):32258-32267.
3BERGER J T,VOYNOW J A,PETERS K W.et al.Respiratory carcinoma cell lines.MUC genes and glycoconjugates[J].Am J Respir Cell Mol Biol,1999,20(3):500-510.
4KITAZAKI T,FUKUDA M,SODA H,et al.Novel effects of gefitinib on mucin production in brenchioloalveolar carcinoma:two case reports[J].Lung Cancer,2005,49(1):125-128.
5RABEN D,HELFRICH B,CIARDIELLO F,et al.Understanding the mechanisms of action of EGFR inhibitors in NSCLC:What we know and what we do not know[J].Lung Cancer,2003,41(Suppl):S15-S22
6FRANKLIN W A,CHANSKY K,GUMERLOCK P H,et al.Association between activation of ErbB pathway genes and survival following gefitinib treatment in advanced BAC(SWOG 0126)[J].J Clin Oncol,2004,22(14S):7015.
7RECK M,GATZEMEIER U.Benefit in lung cancer function imprevement and side-effect prefile of long-term responders:An analysis of 14 NSCLC patients treated for at least 9 months with gefitinib[J].Lung Cancer,2005,50(1):107-114
8HO C,MURRAY N,LASKIN J,et al.Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America[J].Lung Cancer,2005,49(2):225-231.
9CIARDIELLO F,CAPUTO R,BIANCO R,et al.Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839(Iressa),an epidermal growth factor receptor-selective tyrosine kinase inhibitor[J].Clin Cancer Res,2000,6(5):2053-2063.
10SUZUKI T,NAKAGAWA T,ENDO H,et al.The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZDl839(Iressa)is not related to the expression of EGFR or HER-2 or to K-ras gene status[J].Lung Cancer,2003,42(1):35-41.
